SIREN : 850900747
SPFPL PHARMAVENIR 3 is a French company founded 6 years ago, specialized in the sector Gestion de fonds. Based in GRANGUES (14160), this company of category PME shows in 2025 a net income negative of -22 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-18
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Kennzahl | 2025 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Umsatz | N/C | N/C | N/C | N/C | N/C |
| Nettoergebnis | -21 608 € | 202 651 € | 202 901 € | 313 882 € | -87 857 € |
| EBITDA | -4 305 € | -3 097 € | -2 464 € | -3 635 € | -57 582 € |
| Nettomarge | N/C | N/C | N/C | N/C | N/C |
In 2025, SPFPL PHARMAVENIR 3 records a net loss of 22 k€. This deficit will reduce equity on the balance sheet.
-4 305 €
-4 420 €
-21 608 €
The debt ratio (= Financial debt / Equity x 100) stands at 166%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 38%. The balance between equity and debt is satisfactory.
165.919%
37.573%
-142.225
In 2025, the debt ratio of SPFPL PHARMAVENIR 3 (165.92) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2025, the financial autonomy of SPFPL PHARMAVENIR 3 (37.6%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2025, the repayment capacity of SPFPL PHARMAVENIR 3 (-142.22) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 566.81. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
566.814
-208.153
In 2025, the liquidity ratio of SPFPL PHARMAVENIR 3 (566.81) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2025, the interest coverage of SPFPL PHARMAVENIR 3 (-208.2x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 174 days. Excellent situation: suppliers finance 174 days of the operating cycle (retail model).
0 €
0 j
174 j
0 j
Compare SPFPL PHARMAVENIR 3 with other companies in the same sector:
The revenue of SPFPL PHARMAVENIR 3 is not publicly disclosed (confidential accounts filed with INPI).
SPFPL PHARMAVENIR 3 recorded a net loss in 2025.
The headquarters of SPFPL PHARMAVENIR 3 is located in GRANGUES (14160), in the department Calvados.
The tax return of SPFPL PHARMAVENIR 3 is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SPFPL PHARMAVENIR 3 operates in the sector Gestion de fonds (NAF code 66.30Z). See the 'Sector positioning' section above to compare the company with its competitors.